ASH 2018 Update Webinar

Experts discuss data and key takeaways from seven clinically significant acute lymphocytic leukemia (ALL) abstracts presented at the American Society of Hematology (ASH) 2018 meeting. Despite the possibility of remission with induction chemotherapy, mortality has traditionally been unacceptably high for adults diagnosed with ALL. Learn about recent advances in immunotherapy, including CAR-T therapy, as an integral part of the relapsed/refractory ALL treatment paradigm. Abstracts include, but are not limited to, data for moving immunotherapy to the frontline and new strategies for overcoming immune escape for patients with ALL.

Speakers

Firas El Chaer, MDFiras El Chaer, MD
Hematology and Oncology
Marlene & Stewart Greenebaum Comprehensive Cancer Center
University of Maryland

Twitter: @firaselchaer

 

Ashkan EmadiAshkan Emadi, MD, PhD
Professor, Medicine and Pharmacology
Associate Director for Clinical Research; Director, Clinical Research Shared Service
Marlene & Stewart Greenebaum Comprehensive Cancer Center
University of Maryland

Register for On-Demand Replay

 

Our Partner

LLS Logo 

Our Supporter

AMGEN LOGO
This project is sponsored by Amgen

In the News

Clinical Journals